Clinical Trial Update: Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)

View source ↗

Summary

A trial is comparing cognitive effects of Campath (alemtuzumab) versus Rebif (interferon beta-1a) in relapsing-remitting multiple sclerosis. No results or defin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)
• Rebif (interferon beta-1a)

Snippet

Sponsor: Washington Neuropsychology Research Group | Conditions: Relapsing Remitting Multiple Sclerosis | Status: UNKNOWN